Pharnext to Attend January Investor Conferences
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that senior management will be attending the following conferences taking place in January in France:
- Oddo 20 th Midcap Forum on January 5-6 in Lyon Convention Center
- Invest Securities BioMed Event – 2nd Edition - on January 26 in Salons Hoche, Paris
If you are interested in meeting the Pharnext management team during either of these events, please send an email to firstname.lastname@example.org .
Senior management will also be available for meetings in the U.S. in San Francisco, CA from January 9-13 during the 35th Annual J.P. Morgan Healthcare Conference . If you are interested in meeting the Pharnext management team, please send an email to Sarah McCabe at email@example.com .
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY© . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
PLEODRUG© and PLEOTHERAPY© are registered trademarks by Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investors Relations (Europe)
Julie Coulot, +33 (0)1 44 71 20 40
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1-212-362-1200
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Tony Russo, Ph.D., +1-212-845-4251
Matt Middleman, M.D., +1-212-845-4272
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PATIENT-SAFETY-MOVEMENT24.2.2018 11:02 | pressemeddelelse
The 6th Annual World Patient Safety, Science & Technology Summit Kicked off with an Important Announcement about the Progress Being Made to Save Lives in Hospital Settings
CCWW24.2.2018 10:08 | pressemeddelelse
WuQi Technologies is Latest Licensee of CCww’s NB-IoT UE Protocol-Stack Software
IDEMIA23.2.2018 16:59 | pressemeddelelse
IDEMIA and Octo Telematics Reinvent Car Sharing Experience by Adding Facial Recognition to EasyOpen Solution
SM-OPTICS23.2.2018 15:02 | pressemeddelelse
SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes
TX-HASHGAINS23.2.2018 14:58 | pressemeddelelse
Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response
CARDINALITY23.2.2018 14:09 | pressemeddelelse
Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum